Marc Ladanyi
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 0.01%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 212
- Sarcoma Diagnosis and Treatment 152
- Oncology 261
- Lung Cancer Research Studies 69
- Colorectal Cancer Treatments and Studies 54
- HER2/EGFR in Cancer Research 36
- Co-authors
- Mark G. Kris (119 shared papers)Gregory J. Riely (99 shared papers)William Pao (51 shared papers)Maria E. Arcila (115 shared papers)Maureen F. Zakowski (47 shared papers)Cristina R. Antonescu (50 shared papers)Vincent A. Miller (30 shared papers)Pedram Argani (27 shared papers)
- Journals
- Journal of Clinical Oncology (85 papers)Clinical Cancer Research (58 papers)Journal of Thoracic Oncology (41 papers)Modern Pathology (34 papers)Cancer Research (29 papers)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Marc Ladanyi
597 papers receiving 56.1k citations
Marc Ladanyi's Hit Papers
Peers
Comparison fields: 5 of 192
- Pulmonary and Respiratory Medicine 35.6k
- Oncology 24.3k
- Cancer Research 13.2k
- Pathology and Forensic Medicine 7.7k
- Molecular Biology 22.3k
Countries citing papers authored by Marc Ladanyi
This map shows the geographic impact of Marc Ladanyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ladanyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ladanyi more than expected).
Fields of papers citing papers by Marc Ladanyi
This network shows the impact of papers produced by Marc Ladanyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ladanyi. The network helps show where Marc Ladanyi may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc Ladanyi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 617 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks Hit paper breakdown → | 2001 | 1919 |
| 2 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers Hit paper breakdown → | 2013 | 1893 |
| 3 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Hit paper breakdown → | 2005 | 1228 |
| 4 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Hit paper breakdown → | 2013 | 967 |
| 5 | Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation Hit paper breakdown → | 1994 | 809 |
| 6 | Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Hit paper breakdown → | 2006 | 664 |
| 7 | Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib Hit paper breakdown → | 2006 | 623 |
| 8 | Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor Hit paper breakdown → | 2010 | 604 |
| 9 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation Hit paper breakdown → | 2012 | 555 |
| 10 | Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis Hit paper breakdown → | 2009 | 539 |
| 11 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Hit paper breakdown → | 2017 | 521 |
| 12 | The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma Hit paper breakdown → | 2011 | 512 |
| 13 | Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations Hit paper breakdown → | 2011 | 503 |
| 14 | Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers Hit paper breakdown → | 2012 | 493 |
| 15 | 1998 | 490 | |
| 16 | Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Hit paper breakdown → | 2010 | 485 |
| 17 | Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Hit paper breakdown → | 2011 | 476 |
| 18 | 2009 | 467 | |
| 19 | ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer Hit paper breakdown → | 2013 | 460 |
| 20 | 2001 | 457 |
About Marc Ladanyi
Marc Ladanyi is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Pathology and Forensic Medicine, having authored 617 papers that have together received 57.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (212 papers), Cancer Genomics and Diagnostics (156 papers), Sarcoma Diagnosis and Treatment (152 papers), Lung Cancer Research Studies (69 papers), Colorectal Cancer Treatments and Studies (54 papers), Lymphoma Diagnosis and Treatment (50 papers), Renal and related cancers (37 papers) and HER2/EGFR in Cancer Research (36 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (35.6k citations), Oncology (24.3k citations), Cancer Research (13.2k citations), Pathology and Forensic Medicine (7.7k citations) and Molecular Biology (22.3k citations). Marc Ladanyi has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Mark G. Kris, Gregory J. Riely, William Pao, Maria E. Arcila, Maureen F. Zakowski, Cristina R. Antonescu, Vincent A. Miller, Pedram Argani, William L. Gerald and Natasha Rekhtman. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Modern Pathology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.